OPEN SCIENCE DB
  • Research Database
    • Basic Research DB
    • Medical Research DB
    • Engineering DB
  • About us
    • Our Story
    • How It Works
    • Leadership
    • Q&A
    • Contact us
  • How to Participate
    • Guideline for Researchers
    • Guideline for Editors
  • Forum
  • Tech Transfer

Usage of quadrivalent influenza vaccine among children in the United States from 2013 to 2014 - CDC

3/20/2017

Comments

 
Picture
Contributed by Robert Wardlow,
PhD student at Johns Hopkins University
Influenza vaccinations can be administered in primarily two different forms: one form with a live, but critically weakened virus (a.k.a. live attenuated vaccine); the other with a completely inactivated virus. Vaccines are also described by the number of different strains of the flu virus they protect against. Historically, the flu vaccine has protected against 3 different flu strains (trivalent vaccine). During the flu season of 2013-2014, a new variation of the flu vaccine was introduced in the United States. This new quadrivalent vaccine provides protection against four different potential seasonal strains of influenza virus. It is generally recommended that any children above the age of 6 months should receive an annual flu vaccination.
 
In this study, immunization records were analyzed at several sites in Michigan, Minnesota, North Dakota, New York City, Oregon, and Wisconsin in order to assess how the quadrivalent vaccine is being administered compared to the trivalent. At these sites, close to 2 million vaccines were administered to children aged 6 months to 18 years during the 2013-2014 season. Of these vaccinations, 49.8% were inactivated virus trivalent vaccines, 16.4% were inactivated virus quadrivalent vaccines, 30.1% were critically weakened virus quadrivalent vaccines, and 3.7% were unknown. The inactivated virus trivalent vaccine was the most common in every age group except for 5-8 year olds.
 

Since this was the first flu season when quadrivalent vaccines had been used, they were not readily available at all of the sites examined. This might help to explain why they were not used even more commonly.
 
Starting in 2014, the Advisory Committee on Immunization Practices has begun to recommend that healthy children, aged 2-8 years, should preferentially receive the critically weakened virus quadrivalent vaccine. This recommendation, along with increased availability of the new quadrivalent vaccines should increase the percentage of children receiving quadrivalent vaccinations in the future.
 
Although the sites examined in this study may not be a perfect representation of the entire country, they do provide a baseline to begin examining how quickly the quadrivalent vaccines are adopted in the United States.

Original article can be found here:
http://www.sciencedirect.com/science/article/pii/S0264410X15011329 

Can't access the original article? Find out more details about this article on our database:
http://www.opensciencedb.com/federal-agency-research-db.html#federal-research-db/federal-research-db-detail/58d0529b3fdc352e71abf867/




Read a relevant article by written by CDC scientists! 
Only less than half of small children are fully vaccinated against the flu


Comments

    Authors

    We are grad students and scientists dedicated to disseminating 
    ​scientific facts. 

    ​Are you a student or postdoc? We need your help to deliver scientific facts to the public!

    Sign up here

    Categories

    All
    CDC
    EPA
    NPS
    USDA
    USGS

    Archives

    April 2017
    March 2017
    February 2017
    January 2017

Picture
Research Database
Basic Research DB
Medical Research DB
​Engineering DB
How to participate?
Guideline for Researchers
Guideline for Editors
About Us
Our Story
How It Works
Leadership
Q&A
Contact Us
Forum
Tech Transfer
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
  • Research Database
    • Basic Research DB
    • Medical Research DB
    • Engineering DB
  • About us
    • Our Story
    • How It Works
    • Leadership
    • Q&A
    • Contact us
  • How to Participate
    • Guideline for Researchers
    • Guideline for Editors
  • Forum
  • Tech Transfer